2023 World Conference on Lung Cancer (Posters)-EP11.01. The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy

EP11.01. The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigates the value of PD-L1 (Programmed Death-Ligand 1) in circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy. PD-L1 is a biomarker used to predict the response to immunotherapy in NSCLC. The study collected peripheral blood samples from patients before, during, and after immunotherapy. The numbers and genotyping of CTCs were detected using a genotyping assay kit. PD-L1 expression in CTCs was also examined. <br /><br />The study enrolled 81 patients, of which 22 had detectable PD-L1 in tumor tissue. The agreement between PD-L1 in CTCs and tissue samples was 50%. Among the patients with CTC PD-L1 positive, 34 had a partial response and 12 had stable disease. The predicted objective response rate (ORR) was 47.1% and the disease control rate (DCR) was 82.4% in this group. Among the patients with CTC PD-L1 negative, 3 had a partial response and 14 had stable disease. The predicted ORR was 13% and the DCR was 74% in this group. The study also observed that the CTC PD-L1 expression and number decreased at the time of best response and increased at the time of disease progression.<br /><br />The study concludes that PD-L1 expression in CTCs can be easily accessed, especially in patients without tissue samples. It suggests that CTC PD-L1 may have potential in predicting the response to immunotherapy. However, further studies with survival data are needed to validate the value of CTC PD-L1.<br /><br />This research provides insights into the use of CTCs and PD-L1 as potential biomarkers in guiding immunotherapy treatment for NSCLC patients.

Asset Subtitle

Yasi Xu

Meta Tag

Speaker Yasi Xu

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

PD-L1

circulating tumor cells

non-small cell lung cancer

immunotherapy

biomarker

genotyping assay kit

response rate

disease control rate

CTC PD-L1 expression

predicting response to immunotherapy